INSIGHTS ON DRUG DEVELOPMENT

• Why Early Device Decisions Matter: How Immunovant Accelerated Its Program

  Deferring autoinjector selection can seem to preserve flexibility, yet it often moves constraints downstream. Integrating the device during Phase IIb changed one program's timeline and removed bridging work.

• Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD)

  Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.

• Cracking Complexity: Learnings From 70+ Bispecific Antibody Programs

  The goal is practical: help development teams make early decisions that balance speed, quality, and risk and support a smoother path to the clinic.

• The Importance Of Reliable Mixing In ITC Experiments

  Explore how Isothermal Titration Calorimetry (ITC) precisely analyzes molecular interactions, which provides crucial thermodynamic data to understand physiological processes and develop new therapeutic strategies.

• History Of Peptides In Medicine: From Early Chemistry To The GLP-1 Era

  4/21/2026

  Peptide therapeutics from early chemical breakthroughs to today’s metabolic drugs, highlighting scientific, clinical, and manufacturing advances shaping modern drug development.

• Simplify Process Scale-Up With An Innovative Single-Use Bioreactor

  10/15/2025

  Consistent cell growth and protein yields from 5 L to 5,000 L show how a unified bioreactor design can simplify scale-up, reduce risk, and accelerate upstream process development in bioproduction.

• Advancing Cell Culture Strategies To Accelerate Biologics Development

  5/5/2026

  Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks in transitioning from discovery to manufacturing.

• Evaluating Compound Toxicity Effects On Healthy Intestinal Organoids

  3/24/2025

  3D organoids enhance drug toxicity prediction and are crucial for anti-cancer drug development. Examine a method using 3D mouse intestinal organoids that aims to provide vital data on intestinal toxicity.

• Integrating Phase-Appropriate Quality Standards

  12/9/2024

  Incorporating phase-specific quality standards ensures GMP compliance. Collaborating with an experienced CDMO addresses late-stage quality needs and efficiently manages development timelines.